FluxMPS™ RPMI 1640 Medium, High Glucose & 25mM HEPES w/o Sodium Bicarbonate, Phenol Red: 1X Liquid

FluxMPS™ RPMI 1640 Medium, High Glucose & 25mM HEPES w/o Sodium Bicarbonate, Phenol Red: 1X Liquid

FluxMPS™ DCP-RPMIGH-BR1X is a Microfluidics Suitable, ultra-filtered RPMI 1640 formulation engineered for organ-on-a-chip (OoC) and microphysiological system (MPS) platforms. Processed through a quadruple-stage filtration train (0.1 µm ×2 + 0.04 µm ×2) reaching a 0.04 µm final cut-off — five times finer than the 0.22 µm membranes used for conventional sterile filtration — this HEPES-buffered, bicarbonate-free, phenol-red-free formulation is purpose-built for imaging, metabolic flux analysis, and long-duration microfluidic culture.

• High Glucose (4500 mg/L) RPMI 1640 base buffered with 25 mM HEPES
• Bicarbonate-free, phenol-red-free formulation — compatible with Agilent Seahorse XF metabolic flux assays
• Quadruple-stage filtration (0.1 µm ×2 + 0.04 µm ×2) to a 0.04 µm final cut-off
• Endotoxin release specification: < 0.05 EU/mL (LAL, USP <85>)
• L-Glutamine (300 mg/L) and Sodium Pyruvate (110 mg/L) included — ready for immediate culture
• Manufactured under an ISO 13485:2016 quality management system
• 39 verified ingredients with full CAS traceability, per-batch QC release
• Custom pH, glucose, HEPES, and nutrient modifications available on request

Engineered where standard media fails

Conventional 0.22 µm–filtered media passes mycoplasma-sized organisms, subvisible particulates, and endotoxin fragments that confound sensitive cell assays and foul microfluidic channels.

Quadruple-stage filtration system

Four serial filtration stages — two dedicated prefilter-plus-final-filter pairs — reaching a final 0.04 µm polish under aseptic fill conditions.

1. 1

   0.1 µm Prefiltration I

   Removes large aggregates, cell debris, and protein clusters; protects the first 0.04 µm cartridge and extends its service life.

2. 2

   0.04 µm Final filtration I

   First 0.04 µm pass; retains sub-micron particulates and microaggregates that a 0.22 µm filter allows through.

3. 3

   0.1 µm Prefiltration II

   A second, dedicated prefilter protecting the second 0.04 µm cartridge — not a polish of Stage 2’s effluent, but redundant protection for Stage 4.

4. 4

   0.04 µm Final filtration II — Polish

   Ultimate polishing filter ahead of aseptic fill & finish. Final product QC release gate.

OoC and MPS Applications

FluxMPS™ DCP-RPMIGH-BR1X delivers a Microfluidics Suitable, HEPES-buffered, bicarbonate-free, phenol-red-free formulation for organ-on-a-chip and microfluidic applications.

Automated Bioreactors & Robotics

An optional 0.01 µm (10 nm) ultra nano-filtered MPS Grade variant of this formulation is available on request for automated bioreactors and robotic perfusion systems that demand the finest available cut-off.

• Total Particulate Exclusion: 10 nm filtration removes nanoparticulate aggregates that foul automated systems
• Valve & Sensor Protection: Reduces micro-fouling risk in automated perfusion and recirculation systems
• Extended Perfusion Stability: Consistent nutrient delivery over long-duration culture runs

Inquiry Required: Contact support@diagnocine.com to request the 0.01 µm MPS Grade variant.

Analytical release specifications

Every batch released against the full specification matrix. Certificate of Analysis available: support@diagnocine.com.

Full composition (mg/L)

RPMI 1640 Medium, High Glucose & 25mM HEPES w/o Sodium Bicarbonate, Phenol Red: 1X Liquid — 39 ingredients verified per batch with CAS numbers for raw-material traceability. All ingredients from the original formulation are preserved exactly.

ISO 13485 Manufacturing & Compliance

Every batch of FluxMPS™ DCP-RPMIGH-BR1X is manufactured under a certified ISO 13485:2016 QMS with full lot traceability and multi-parameter QC release testing.

How DCP-RPMIGH-BR1X compares

FluxMPS™ versus conventional 0.22 µm filtered media for OoC and MPS applications.

Comparison figures from published supplier specifications, accessed 2026-09-02. Suppliers that publish no numeric endotoxin specification are shown as "Not specified".

Frequently asked questions

Common questions about FluxMPS™ DCP-RPMIGH-BR1X and its use in OoC and MPS applications.

Supporting literature

Curated peer-reviewed references relevant to OoC and MPS applications and FluxMPS™ ultra-filtered cell culture media.

1. Bhatia SN, Ingber DE. Microfluidic organs-on-chips. Nature Biotechnology. 2014;32(8):760–772.doi:10.1038/nbt.2989
2. Sackmann EK, Fulton AL, Beebe DJ. The present and future role of microfluidics in biomedical research. Nature. 2014;507(7491):181–189.doi:10.1038/nature13118
3. Huh D, et al. Reconstituting organ-level lung functions on a chip. Science. 2010;328(5986):1662–1668.doi:10.1126/science.1188302
4. Ingber DE. Is it Time for Reviewer 3 to Request Human Organ Chip Experiments Instead of Animal Validation Studies? Advanced Science. 2020;7(22):2002162.doi:10.1002/advs.202002162
5. Maoz BM, et al. A linked organ-on-chip model of the human neurovascular unit reveals the metabolic landscape of brain disease. Nature Biotechnology. 2018;36:865–874.doi:10.1038/nbt.4226
6. Bhise NS, et al. A liver-on-a-chip platform with bioprinted hepatic spheroids. Biofabrication. 2016;8(1):014101.doi:10.1088/1758-5090/8/1/014101
7. Luni C, Serena E, Elvassore N. Human-on-chip for therapy development and fundamental science. Current Opinion in Biotechnology. 2014;25:45–50.doi:10.1016/j.copbio.2013.08.015
8. Erickson KA, Bhansali S. Mycoplasma contamination in cell cultures: a survey of incidence and approaches to prevention. Journal of the Association for Laboratory Automation. 2012;17(5):346–354.doi:10.1177/2211068212456089
9. van Duinen V, et al. Microfluidic 3D cell culture: from tools to tissue models. Current Opinion in Biotechnology. 2015;35:118–126.doi:10.1016/j.copbio.2015.05.002
10. Warburg O. On the origin of cancer cells. Science. 1956;123(3191):309–314.doi:10.1126/science.123.3191.309